MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Watch List: Layoffs of 10% or More, Strategic Corporate Review, Delisting, Regulatory, Financial and/or Legal Issues
Lyell Immunopharma, Inc (NASDAQ: LYEL)*
Organization & Developments: Lyell
Parents
Lyell Immunopharma, Inc (NASDAQ: LYEL)*
Children
2023: Lyell Immunopharma: Potential Solid Tumor Targeting With CAR-T And TIL
2023: Lyell lays off 25% of staff and CMO leaves as company foreshadows first clinical data next year
Cellular therapy company dedicated to mastering immune cell functionality.
Focused on advancing the science of t-cell differentiation, functionality, and specificity so they can develop curative treatments for human disease.
Its technologies are designed to be applied in a target and agnostic manner to chimeric antigen receptor (CAR), tumor-infiltrating lymphocytes (TIL) and T cell receptor (TCR) therapies to improve the properties of T cells to eradicate solid tumors
Jumps
*Key People: Lyell
Finance & Acquisitions: Lyell